Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 438-449

  Vulih Shultzman, Inna ^a   Pinhasov, Albert ^a   Mandel, Shmuel ^a   Grigoriadis, Nikolaos ^b   Touloumi, Olga ^b   Pittel, Zipora ^a   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN; NERVE PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; MEMORY DISORDER; MOUSE; NERVE DEGENERATION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TAUOPATHY;

ANIMALS; ASTROCYTES; COGNITION DISORDERS; FEMALE; HOMEODOMAIN PROTEINS; LEARNING; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; OLIGOPEPTIDES; PHOSPHORYLATION; TAU PROTEINS;

EID: 35548974346     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.129551     Document Type: Article

References (40)

1. Alcalay RN, Giladi E, Pick CG, and Gozes I (2004) Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 361:128-131.
2. Anderson KJ, Miller KM, Fugaccia I, and Scheff SW (2005) Regional distribution of fluoro-jade B staining in the hippocampus following traumatic brain injury. Exp Neurol 193:125-130.
3. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72:1283-1293.
4. Borozdin W, Graham JM Jr, Bohm D, Bamshad MJ, Spranger S, Burke L, Leipoldt M, and Kohlhase J (2007) Multigene deletions on chromosome 20q13.13-q13.2 including SALL4 result in an expanded phenotype of Okihiro syndrome plus developmental delay. Hum Mutat 28:830.
5. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, and Jope RS (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55:3320-3325.
6. Dabir DV, Robinson MB, Swanson E, Zhang B, Trojanowski JQ, Lee VM, and Forman MS (2006) Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J Neurosci 26:644-654.
7. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, and Gozes I (2006) Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 98:973-984.
8. Divinski I, Mittelman L, and Gozes I (2004) A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279:28531-28538.
9. Forman MS, Zhukareva V, Bergeron C, Chin SS, Grossman M, Clark C, Lee VM, and Trojanowski JQ (2002) Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol 160:2045-2053.
10. Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, and Feany MB (2007) Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol 9:139-148.
11. Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, and Gozes I (2005) Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett 373:73-78.
12. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, and Gozes I (2004) Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biology 1:193-199.
13. Gozes I and Divinski I (2004) The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J Alzheimers Dis 6:S37-41.
14. Gozes I, Giladi E, Pinhasov A, Bardea A, and Brenneman DE (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293:1091-1098.
15. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, et al. (2005a) NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11:353-368.
16. Gozes I and Sweadner KJ (1981) Multiple tubulin forms are expressed by a single neurone. Nature 294:477-480.
17. Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, and Hill JM (2005b) The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2:149-153.
18. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, et al. (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61:59-66.
19. Hill JM, Hauser JM, Sheppard LM, Abebe D, Spivak-Pohis I, Kushnir M, Deitch I, and Gozes I (2007) Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci 31:183-200.
20. Klupa T, Malecki MT, Pezzolesi M, Ji L, Curtis S, Langefeld CD, Rich SS, Warram JH, and Krolewski AS (2000) Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes 49:2212-2216.
21. Mandel S, Rechavi G, and Gozes I (2007) Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol 303:814-824.
22. Mandelkow EM, Stamer K, Vogel R, Thies E, and Mandelkow E (2003) Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24:1079-1085.
23. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, Laferla FM, Gozes I, and Aisen PS (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31:165-170.
24. Modrego PJ (2006) Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 3:161-170.
25. Pascual M and Guerri C (2007) The peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanol. J Neurochem, in press.
26. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, and Gozes I (2003) Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 144:83-90.
27. Plattner F, Angelo M, and Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281:25457-25465.
28. Ransom B, Behar T, and Nedergaard M (2003) New roles for astrocytes (stars at last). Trends Neurosci 26:520-522.
29. Sato M, Chang E, Igarashi T, and Noble LJ (2001) Neuronal injury and loss after traumatic brain injury: time course and regional variability. Brain Res 917:45-54.
30. Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad B, and Bogdanovi (2000) nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. Exp Neurol 165:12-26.
31. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, and Plata-Salaman CR (2005) Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 25:225-238.
32. Steingart RA and Gozes I (2006) Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol 252:148-153.
33. Stoykova A and Gruss P (1994) Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J Neurosci 14:1395-1412.
34. Togo T and Dickson DW (2002) Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Acta Neuropathol (Berl) 104:398-402.
35. Tolnay M and Probst A (1999) Review: tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 25:171-187.
36. Veeranna, Shetty KT, Takahashi M, Grant P, and Pant HC (2000) Cdk5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain. Brain Res Mol Brain Res 76:229-236.
37. Vink J, Auth J, Abebe DT, Brenneman DE, and Spong CY (2005) Novel peptides prevent alcohol-induced spatial learning deficits and proinflammatory cytokine release in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol 193:825-829.
38. Wang JZ, Grundke-Iqbal I, and Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25:59-68.
39. Zaltzman R, Alexandrovich A, Beni SM, Trembovler V, Shohami E, and Gozes I (2004) Brain injury-dependent expression of activity-dependent neuroprotective protein. J Mol Neurosci 24:181-187.
40. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, et al. (2001) Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 276:708-714.